RCS - Faron Pharma. Oy - Faron announces Capital Markets Day

Faron Pharmaceuticals OyAnnouncement

07/10/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241007:nRSG0862Ha&default-theme=true

RNS Number : 0862H  Faron Pharmaceuticals Oy  07 October 2024

Faron Pharmaceuticals Ltd.

 

("Faron" or "the Company")

 

Faron announces Capital Markets Day to be held on 22 October 2024

 

Press release, 7 October 2024

 

TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a
clinical-stage biopharmaceutical company focused on tackling cancers via novel
immunotherapies, today announces that it will host a Capital Markets Day for
investors, analysts and media on Tuesday, 22 October 2024 at 08:00 am (EDT) /
13:00 pm (BST) / 15:00 pm (EEST). Speakers include Dr. Mika Kontro, MD, PhD,
Associate Professor at the University of Helsinki, Mr. Ralph Hughes, MSc,
BSc, Senior Vice President at PharmaVentures and members of Faron's senior
management team.

 

The agenda is as follows:

 

·    Opening remarks

·    Faron's strategy and key focus areas - Dr. Juho Jalkanen, MD, PhD,
CEO

·    BEXMAB clinical data - Dr. Mika Kontro, MD, PhD, principal
investigator of the BEXMAB trial

·    BEXMAB MDS market assessment - Mr. Ralph Hughes, MSc, BSc

·    Faron's development plan for solid tumors - Dr. Petri Bono, MD, PhD,
CMO

·    Who benefits from bexmarilimab and why - Future Addressable Markets -
Dr. Maija Hollmén, PhD, CSO

·    Q&A session

·    Closing remarks

 

As part of the event, Juho Jalkanen, CEO of Faron, will discuss Faron's
strategy and key focus areas for the coming years. Dr. Kontro will share
updated survival data from the ongoing BEXMAB Phase I/II trial. Mr. Hughes
will present the results of recently conducted market research in MDS. Dr.
Bono will provide Faron's development plan for solid tumours, discuss
bexmarilimab's further potential as first-in-class immune-oncological
treatment and introduce the Company's new Scientific Advisory Board (SAB).

 

"I am delighted to be hosting this Capital Markets Day with our invited
speakers and members of Faron's senior management team who will provide
important insights into the recent developments and further plan to bring the
promise of immunotherapy to a broader patient group," said Dr. Juho Jalkanen,
Chief Executive Officer of Faron. "In addition to providing the latest BEXMAB
survival update, we will present the clinical development plan for
bexmarilimab in solid tumors. The event will also feature an introduction to
our new Scientific Advisory Board with world-leading clinical investigators,"
said Dr. Petri Bono, Chief Medical Officer at Faron.

 

The event will be held as a live hybrid event. It will begin at 08:00 am (EDT)
/ 13:00 pm (BST) / 15:00 pm (EEST) on Tuesday, October 22, 2024. The duration
of the event will be some 2.5 hours.

 

Webcast registration link: https://faron.videosync.fi/cmd-2024
(https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Ffaron.videosync.fi%2Fcmd-2024&data=05%7C02%7C%7C8a10b91402394e05c18908dce120fe18%7Ca2d9b7a432f64a96b03727499230d5fd%7C1%7C0%7C638632779058056764%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=pVPpycYNfzWXHWXRI%2FVKZwwq6XNlTa8LGFE69VhBZ%2Fg%3D&reserved=0)

 

 

Live participation

In addition to the webcast, there are a limited number of seats available to
attend the Capital Markets Day at Eliel in Sanomatalo at Töölönlahdenkatu
2, Helsinki. To register, please contact

investor.relations@faron.com (mailto:investor.relations@faron.com)  no later
than 2:00 pm (EEST) on Friday, 18 October 2024. Please note that places are
limited, and you will receive a separate email if you get a seat confirmed.

 

A link to a recording of this Capital Markets Day will be made available on
the "Investors" section on Faron's website at:
 https://www.faron.com/investors (https://www.faron.com/investors) .

 

 

For more information please contact:

ICR Consilium
Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com (mailto:faron@consilium-comms.com)

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

About BEXMAB

 

The BEXMAB study is an open-label Phase I/II clinical trial investigating
bexmarilimab in combination with standard of care (SoC) in the aggressive
hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic
syndrome (MDS). The primary objective is to determine the safety and
tolerability of bexmarilimab in combination with SoC (azacitidine) treatment.
Directly targeting Clever-1 could limit the replication capacity of cancer
cells, increase antigen presentation, ignite an immune response, and allow
current treatments to be more effective. Clever-1 is highly expressed in both
AML and MDS and associated with therapy resistance, limited T cell activation
and poor outcomes.

 

About bexmarilimab

 

Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed
to overcome resistance to existing treatments and optimize clinical outcomes,
by targeting myeloid cell function and igniting the immune system.
Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on
macrophages leading to tumor growth and metastases (i.e. helps cancer evade
the immune system). By targeting the Clever-1 receptor on macrophages,
bexmarilimab alters the tumor microenvironment, reprogramming macrophages from
an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating
interferon production and priming the immune system to attack tumors and
sensitizing cancer cells to standard of care.

 

About Faron Pharmaceuticals Ltd

 

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The Company's lead asset is bexmarilimab, a novel
anti-Clever-1 humanized antibody, with the potential to remove
immunosuppression of cancers through reprogramming myeloid cell function.
Bexmarilimab is being investigated in Phase I/II clinical trials as a
potential therapy for patients with hematological cancers in combination with
other standard treatments. Further information is available at www.faron.com
(http://www.faron.com) .

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUNOWRSKURRAA